STAT1-HDAC4 signaling induces epithelial-mesenchymal transition and sphere formation of cancer cells overexpressing the oncogene, CUG2

被引:41
作者
Kaowinn, Sirichat [1 ]
Kaewpiboon, Chutima [2 ]
Koh, Sang Seok [3 ]
Kraemer, Oliver H. [4 ]
Chung, Young-Hwa [1 ]
机构
[1] Pusan Natl Univ, Dept Cogno Mechatron Engn, BK21, Busan 46241, South Korea
[2] Thaksin Univ, Fac Sci, Dept Biol, Phatthalung 93210, Thailand
[3] Dong A Univ, Dept Biol Sci, Busan 49315, South Korea
[4] Univ Med Ctr Mainz, Dept Toxicol, D-55131 Mainz, Germany
关键词
CUG2; STAT1; HDAC4; epithelial-mesenchymal transition; sphere formation; REGULATED GENE 2; PHOSPHORYLATION-ACETYLATION SWITCH; OVARIAN-CANCER; CONFERS RESISTANCE; INDUCED APOPTOSIS; MULTIPLE-MYELOMA; STAT1; ACTIVATION; DOWN-REGULATION; BREAST-CANCER; HDAC4;
D O I
10.3892/or.2018.6701
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Our previous studies have shown that the novel oncogene, cancer upregulated gene 2 (CUG2), activates STAT1, which is linked to anticancer drug resistance, induces epithelial-mesenchymal transition (EMT) and cancer stem cell-like phenotypes as determined by MTT, migration and sphere formation assays. We thus aimed to ascertain whether the activation of STAT1 by CUG2 is involved in these malignant phenotypes besides drug resistance. Here, we showed that STAT1 suppression decreased the expression of N-cadherin and vimentin, biomarkers of EMT, which led to inhibition of the migration and invasion of human lung A549 cancer cells stably expressing CUG2, but did not recover E-cadherin expression. STAT1 siRNA also diminished CUG2-induced TGF-beta signaling, which is critical in EMT, and TGF-beta transcriptional activity. Conversely, inhibition of TGF-beta signaling reduced phosphorylation of STAT1, indicating a crosstalk between STAT1 and TGF-beta signaling. Furthermore, STAT1 silencing diminished sphere formation, which was supported by downregulation of stemness-related factors such as Sox2, Oct4, and Nanog. Constitutive suppression of STAT1 also inhibited cell migration, invasion and sphere formation. As STAT1 acetylation counteracts STAT1 phosphorylation, acetylation of STAT1 by treatment with trichostatin A, an inhibitor of histone deacetylases (HDACs), reduced cell migration, invasion, and sphere formation. As HDAC4 is known to target STAT1, its role was investigated under CUG2 overexpression. HDAC4 suppression resulted in inhibition of cell migration, invasion, and sphere formation as HDAC4 silencing hindered TGF-beta signaling and decreased expression of Sox2 and Nanog. Taken together, we suggest that STAT1-HDAC4 signaling induces malignant tumor features such as EMT and sphere formation in CUG2-overexpressing cancer cells.
引用
收藏
页码:2619 / 2627
页数:9
相关论文
共 37 条
  • [1] Activation of the STAT signaling pathway can cause expression of caspase 1 and apoptosis
    Chin, YE
    Kitagawa, M
    Kuida, K
    Flavell, RA
    Fu, XY
    [J]. MOLECULAR AND CELLULAR BIOLOGY, 1997, 17 (09) : 5328 - 5337
  • [2] Cell growth arrest and induction of cyclin-dependent kinase inhibitor p21(WAF1/CIP1) mediated by STAT1
    Chin, YE
    Kitagawa, M
    Su, WCS
    You, ZH
    Iwamoto, Y
    Fu, XY
    [J]. SCIENCE, 1996, 272 (5262) : 719 - 722
  • [3] STAT1 signaling is associated with acquired crossresistance to doxorubicin and radiation in myeloma cell lines
    Fryknas, Marten
    Dhar, Sumeer
    Oberg, Fredrik
    Rickardson, Linda
    Rydaker, Maria
    Goransson, Hanna
    Gustafsson, Mats
    Pettersson, Ulf
    Nygren, Peter
    Larsson, Rolf
    Isaksson, Anders
    [J]. INTERNATIONAL JOURNAL OF CANCER, 2007, 120 (01) : 189 - 195
  • [4] HDAC4 Protein Regulates HIF1α Protein Lysine Acetylation and Cancer Cell Response to Hypoxia
    Geng, Hao
    Harvey, Chris T.
    Pittsenbarger, Janet
    Liu, Qiong
    Beer, Tomasz M.
    Xue, Changhui
    Qian, David Z.
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2011, 286 (44) : 38095 - 38102
  • [5] Clinical significance of histone deacetylase (HDAC)-1, HDAC-2, HDAC-4, and HDAC-6 expression in human malignant and benign thyroid lesions
    Giaginis, Constantinos
    Alexandrou, Paraskevi
    Delladetsima, Ioanna
    Giannopoulou, Ioanna
    Patsouris, Efstratios
    Theocharis, Stamatios
    [J]. TUMOR BIOLOGY, 2014, 35 (01) : 61 - 71
  • [6] Histone deacetylase inhibitors block IFNγ-induced STAT1 phosphorylation
    Ginter, Torsten
    Bier, Carolin
    Knauer, Shirley K.
    Sughra, Kalsoom
    Hildebrand, Dagmar
    Muenz, Tobias
    Liebe, Theresa
    Heller, Regine
    Henke, Andreas
    Stauber, Roland H.
    Reichardt, Werner
    Schmid, Johannes A.
    Kubatzky, Katharina F.
    Heinzel, Thorsten
    Kraemer, Oliver H.
    [J]. CELLULAR SIGNALLING, 2012, 24 (07) : 1453 - 1460
  • [7] CCAN Makes Multiple Contacts with Centromeric DNA to Provide Distinct Pathways to the Outer Kinetochore
    Hori, Tetsuya
    Amano, Miho
    Suzuki, Aussie
    Backer, Chelsea B.
    Welburn, Julie P.
    Dong, Yimin
    McEwen, Bruce F.
    Shang, Wei-Hao
    Suzuki, Emiko
    Okawa, Katsuya
    Cheeseman, Iain M.
    Fukagawa, Tatsuo
    [J]. CELL, 2008, 135 (06) : 1039 - 1052
  • [8] Autocrine PDGFR signaling promotes mammary cancer metastasis
    Jechlinger, Martin
    Sommer, Andreas
    Moriggl, Richard
    Seither, Peter
    Kraut, Norbert
    Capodiecci, Paola
    Donovan, Michael
    Cordon-Cardo, Carlos
    Beug, Hartmut
    Gruenert, Stefan
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 2006, 116 (06) : 1561 - 1570
  • [9] Histone Deacetylase HDAC4 Promotes Gastric Cancer SGC-7901 Cells Progression via p21 Repression
    Kang, Zhen-Hua
    Wang, Chun-Yan
    Zhang, Wen-Liang
    Zhang, Jian-Tao
    Yuan, Chun-Hua
    Zhao, Ping-Wei
    Lin, Yu-Yang
    Hong, Sen
    Li, Chen-Yao
    Wang, Lei
    [J]. PLOS ONE, 2014, 9 (06):
  • [10] Increased EGFR expression induced by a novel oncogene, CUG2, confers resistance to doxorubicin through Stat1-HDAC4 signaling
    Kaowinn, Sirichat
    Jun, Seung Won
    Kim, Chang Seok
    Shin, Dong-Myeong
    Hwang, Yoon-Hwae
    Kim, Kyujung
    Shin, Bosung
    Kaewpiboon, Chutima
    Jeong, Hyeon Hee
    Koh, Sang Seok
    Kraemer, Oliver H.
    Johnston, Randal N.
    Chung, Young-Hwa
    [J]. CELLULAR ONCOLOGY, 2017, 40 (06) : 549 - 561